These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 22477414)

  • 1. Efficacy and safety of a single 2 mg dose or 4 mg double dose of alteplase for 50 occluded chest ports using a unique instillation technique.
    Sharma RP; Ree CJ; Ree A
    Int J Angiol; 2008; 17(3):125-8. PubMed ID: 22477414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alteplase for the treatment of central venous catheter occlusion in children: results of a prospective, open-label, single-arm study (The Cathflo Activase Pediatric Study).
    Blaney M; Shen V; Kerner JA; Jacobs BR; Gray S; Armfield J; Semba CP;
    J Vasc Interv Radiol; 2006 Nov; 17(11 Pt 1):1745-51. PubMed ID: 17142704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial--the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial.
    Ponec D; Irwin D; Haire WD; Hill PA; Li X; McCluskey ER;
    J Vasc Interv Radiol; 2001 Aug; 12(8):951-5. PubMed ID: 11487675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of occluded central venous catheters with alteplase: results in 1,064 patients.
    Semba CP; Deitcher SR; Li X; Resnansky L; Tu T; McCluskey ER;
    J Vasc Interv Radiol; 2002 Dec; 13(12):1199-205. PubMed ID: 12471182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the cardiovascular thrombolytic to open occluded lines trial.
    Deitcher SR; Fesen MR; Kiproff PM; Hill PA; Li X; McCluskey ER; Semba CP;
    J Clin Oncol; 2002 Jan; 20(1):317-24. PubMed ID: 11773185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant tissue plasminogen activator (alteplase) for restoration of function to occluded central venous catheters in pediatric patients.
    Shen V; Li X; Murdock M; Resnansky L; McCluskey ER; Semba CP;
    J Pediatr Hematol Oncol; 2003 Jan; 25(1):38-45. PubMed ID: 12544772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alteplase for treatment of occluded peripherally inserted central catheters: safety and efficacy in 240 patients.
    Ng R; Li X; Tu T; Semba CP
    J Vasc Interv Radiol; 2004 Jan; 15(1 Pt 1):45-9. PubMed ID: 14709686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant urokinase for restoration of patency in occluded central venous access devices. A double-blind, placebo-controlled trial.
    Haire WD; Deitcher SR; Mullane KM; Jaff MR; Firszt CM; Schulz GA; Schuerr DM; Schwartz LB; Mouginis TL; Barton RP
    Thromb Haemost; 2004 Sep; 92(3):575-82. PubMed ID: 15351854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alteplase infusion versus dwell for clearance of partially occluded central venous catheters in critically ill pediatric patients.
    Ragsdale CE; Oliver MR; Thompson AJ; Evans MC
    Pediatr Crit Care Med; 2014 Jul; 15(6):e253-60. PubMed ID: 24751787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, dose, and timing of reteplase in treating occluded central venous catheters in children with cancer.
    Terrill KR; Lemons RS; Goldsby RE
    J Pediatr Hematol Oncol; 2003 Nov; 25(11):864-7. PubMed ID: 14608195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and economic evaluation of a volume-based cathflo activase protocol versus a fixed-dose alteplase protocol for catheter occlusions in pediatric patients.
    Gilarde JA; Chung AM; Vidal R; Falkos S
    J Pediatr Pharmacol Ther; 2006 Oct; 11(4):237-44. PubMed ID: 23115540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant tissue plasminogen activator to restore catheter patency: efficacy and safety analysis from a multihospital NICU system.
    Scott DM; Ling CY; MacQueen BC; Baer VL; Gerday E; Christensen RD
    J Perinatol; 2017 Mar; 37(3):291-295. PubMed ID: 27831547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alteplase versus urokinase for occluded hemodialysis catheters.
    Zacharias JM; Weatherston CP; Spewak CR; Vercaigne LM
    Ann Pharmacother; 2003 Jan; 37(1):27-33. PubMed ID: 12503929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alteplase for blood flow restoration in hemodialysis catheters: a multicenter, randomized, prospective study comparing "dwell" versus "push" administration.
    Vercaigne LM; Zacharias J; Bernstein KN
    Clin Nephrol; 2012 Oct; 78(4):287-96. PubMed ID: 22541682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteplase for the treatment of catheter occlusion in pediatric patients.
    Anderson DM; Pesaturo KA; Casavant J; Ramsey EZ
    Ann Pharmacother; 2013 Mar; 47(3):405-9. PubMed ID: 23463740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiologic placement of a low profile implantable venous access port in a pediatric population.
    Nosher JL; Bodner LJ; Ettinger LJ; Siegel RL; Gribbin C; Asch J; Drachtman RA
    Cardiovasc Intervent Radiol; 2001; 24(6):395-9. PubMed ID: 11907746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safe and cost effective use of alteplase for the clearance of occluded central venous access devices.
    Timoney JP; Malkin MG; Leone DM; Groeger JS; Heaney ML; Keefe DL; Klang M; Lucarelli CD; Muller RJ; Eng SL; Connor M; Small TN; Brown AE; Saltz LB
    J Clin Oncol; 2002 Apr; 20(7):1918-22. PubMed ID: 11919252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alteplase vs. urokinase for occluded hemodialysis catheter: A randomized trial.
    Pollo V; Dionízio D; Bucuvic EM; Castro JH; Ponce D
    Hemodial Int; 2016 Jul; 20(3):378-84. PubMed ID: 26851872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective analysis of large-dose intrapleural alteplase for complicated pediatric parapneumonic effusion and empyema.
    Taylor JL; Liu M; Hoff DS
    J Pediatr Pharmacol Ther; 2015; 20(2):128-37. PubMed ID: 25964730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial.
    Gusev EI; Martynov MY; Nikonov AA; Shamalov NA; Semenov MP; Gerasimets EA; Yarovaya EB; Semenov AM; Archakov AI; Markin SS;
    Lancet Neurol; 2021 Sep; 20(9):721-728. PubMed ID: 34418399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.